Clinuvel Pharmaceuticals Ltd | CUV

Clinuvel Pharmaceuticals Ltd traded at 16.02 this Thursday July 7th, decreasing 0.22 or 1.35 percent since the previous trading session. Looking back, over the last four weeks, Clinuvel Pharmaceuticals Ltd lost 3.89 percent. Over the last 12 months, its price fell by 42.10 percent. Looking ahead, we forecast Clinuvel Pharmaceuticals Ltd to be priced at 14.85 by the end of this quarter and at 13.84 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
16.02
Daily Change
-1.35%
Yearly
-42.10%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Avita Therapeutics Inc 1.68 0.02 0.90% -68.22%
Mesoblast Ltd 0.83 0.02 1.85% -59.76%
Opthea Ltd 1.17 0.01 0.87% -12.41%
Paradigm Biopharmaceuticals Ltd 1.00 -0.01 -0.50% -50.98%
Pacific Edge 0.71 0 0% -42.28%
PYC Therapeutics Ltd 0.07 0.004 6.06% -54.84%
Telix Pharmaceuticals Ltd 5.19 0.39 8.13% -9.11%

Indexes Price Day Year
AUALL 6786 2.20 0.03% -10.88%
AU200 6597 2.96 0.04% -10.13%

Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.